Race Oncology Limited (ASX: RAC) (Race) is pleased to release an updatedinvestor presentation and invite investors to join a special online investor briefing. Updated Presentation An update on the Company’s Three Pillar strategy and recent related highlights Updates to the…
In >40 clinical trials, Bisantrene has been shown to have low cardiotoxicity This study will assess the molecular mechanisms of Bisantrene heart safety usingcurrent molecular biology techniques Led by an established chemotherapeutic cardiology experienced team at the University of Newcastle…
Former Senior Vice President of Clinical Development at Syneos Health Dr Fuller brings over 30 years’ experience in oncology, international markets, listedbusinesses and is a highly experienced pharmaceutical physician Appointment follows an intensive two-month recruitment process to find a CMO…
Professor Jianjun Chen of the City of Hope Hospital appointed to Race’s Scientific Advisory Board Prof Chen is one of the foremost leaders in the m6A RNA methylation field and discovered Bisantrene’s FTO-inhibiting activity His expertise will be instrumental in…
Bisantrene shown by the University of Chicago to target the Fat Mass and Obesity associated protein (FTO) Bisantrene able to treat skin cancer in mice via inhibition of FTO at non-toxic concentrations Confirms earlier FTO-targeted Bisantrene results by the City…
Race updates its Three Pillar Strategy, detailing intended programs and activities The update confirms progress on all Three Pillars, and shares concrete steps towards increasing value for Bisantrene, through its application to broader cancer indications Committed programs are funded through…
Race enters a collaborative preclinical research program with The University of Newcastle to support the use of Bisantrene in the treatment of extramedullary acute myeloid leukaemia (AML) Research designed to support the use of Bisantrene to treat this form of…
Race enters a collaborative preclinical research program with The University of Newcastle to explore use of Bisantrene as a novel FTO-directed treatment for clear cell renal cell carcinoma (ccRCC) Research designed to demonstrate the utility of Bisantrene to treat this…
Race enters collaborative preclinical research program with The University of Newcastle to explore use of Bisantrene as a novel FTO directed treatment for melanoma Research designed to identify drug combinations that improve upon current standard of care melanoma treatment with…
Race Oncology Limited (ASX: RAC) is pleased to share the final results of our collaborative preclinical research program with the eminent cancer researcher, Associate Professor Nikki Verrills of The University of Newcastle and Hunter Medical Research Institute. The aim of…
